4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Aktis Oncology, Inc. (AKTS) operates in the Biotechnology industry and is headquartered in Boston, United States with about 79 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, AKTS reported $6M in revenue and ($64M) in net income.
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers.
Interactive charts & full statements → Open the AKTS valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $6M | $2M | $0M | $0M |
| Operating Income (EBIT) | ($75M) | ($52M) | ($35M) | ($20M) |
| Net Income | ($64M) | ($44M) | ($29M) | ($18M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total Revenue | $3M | $2M | $1M | $1M |
| Operating Income (EBIT) | ($23M) | ($17M) | ($18M) | ($16M) |
| Net Income | ($18M) | ($15M) | ($15M) | ($12M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets | $265M | $326M | $122M | $138M |
| Total Liabilities | $411M | $414M | $169M | $158M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AKTS viewer.
About TickerBase · Data methodology & sources